Studies on the interaction between interleukin 6 and human malignant nonhematopoietic cell lines

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Previous studies demonstrated that certain hematopoietic growth factors stimulate clonal growth in human solid tumor cell lines.
• Recombinant human interleukin 6 (rhIL-6) is a cytokine with diverse biological activities, including roles in inflammation and immunity.

Purpose of the Study:

• To investigate the effects of rhIL-6 on the proliferation and clonal growth of various human solid tumor cell lines.
• To determine if rhIL-6 influences the growth of nonhematopoietic malignant cells, particularly those previously responsive to other growth factors.

Main Methods:

• Tested rhIL-6 on 26 human solid tumor cell lines from diverse origins (e.g., head and neck, lung, breast, renal).
• Assessed cell growth using tritiated thymidine uptake and a human tumor cloning assay.
• Evaluated the effect of neutralizing anti-hIL-6 antibody on kidney carcinoma cell lines.

Main Results:

• rhIL-6 did not reproducibly enhance or inhibit tritiated thymidine uptake in any tested cell lines.
• No stimulation of clonal growth by rhIL-6 was observed in 19 clonogenic tumor cell lines.
• Cell lines previously sensitive to rhIL-3 and rhGM-CSF showed no sensitivity to rhIL-6.

Conclusions:

• rhIL-6 does not appear to significantly interact with the growth of the tested human solid tumor cell lines of nonhematopoietic origin.
• Autocrine growth-modulating loops involving IL-6 are unlikely in the tested kidney carcinoma cell lines.
• These findings suggest rhIL-6 may not be a direct growth factor for a broad range of solid tumors.